Tutkijat / Oulu  | Ala-Kokko, L. |
| Ala-Kokko, T(ero) |
| Ala-Korpela, M(ika) |
| Alahuhta, S. |
| Alén, M(arkku) |
| Antikainen, R. |
| Anttonen, V(uokko) |
| Biancari, F(austo) |
| Bloigu, R(isto) |
| Eskelinen, S. |
| Flinkkilä, T(apio) |
| Hakkola, J. |
| Hallman, M. |
| Hartikainen, A(nna)-L(iisa) |
| Hausen, H. |
| Hautala, N(ina) |
| Hautala, T(imo) |
| Heape, A. |
| Herzig, K(arl)-H(einz) |
| Hillbom, M. |
| Hiltunen, J.K. |
| Hörkko, S. |
| Huikuri, H(eikki) |
| Hukkanen J(anne) |
| Ignatius, J. |
| Isohanni, M. |
| Jaakkola, J. |
| Jaakkola, M(aritta) S. |
| Jaakola, V-P. |
| Jämsä, T(imo) |
| Janhonen, S. |
| Jartti, T(uomas) |
| Järvelin, M(arjo)-R(iitta) |
| Jokelainen, J(ari) |
| Juffer, A(ndré) H. |
| Junttila, J(uhani) |
| Juvonen, T. |
| Kaarteenaho, R(iitta) |
| Kajantie, E(ero)*(THL/OY) |
| Karppinen (Koivunen), P(eppi) |
| Karppinen, J(aro) |
| Karttunen, T.J. |
| Keinänen-Kiukaanniemi, S(irkka) |
| Kerkelä, R(isto) |
| Kesäniemi, Y(rjö) A(ntero) |
| Kettunen, J(ohannes) |
| Kietzmann, T(homas). |
| Kivirikko, K.I. |
| Knuuttila, M. |
| Koivukangas, J. |
| Kursula, P(etri) |
| Kyngäs, H. |
| Larivaara, P. |
| Larmas, M. |
| Lehenkari, P(etri) |
| Lehtiö, L(ari) |
| Leppilahti, J. |
| Luukinen, H. |
| Mainio A |
| Majamaa, K. |
| Mäki, P(irjo) |
| Mäkikallio, T(imo) H. |
| Männikkö, M(inna) |
| Manninen, A(ki). |
| Martikainen, H(annu) |
| Miettunen, J(ouko) |
| Myllyharju, J(ohanna) |
| Myllylä, R. |
| Myllylä, V. |
| Näyhä, S(imo) |
| Neubauer, P. |
| Nieminen, M(iika) T. |
| Nieminen, P(entti) |
| Niinimäki, J(aakko) |
| Ohukainen, P(auli) |
| Oikarinen, A. |
| Oikarinen, K. |
| Pelkonen, O(lavi) |
| Petäjä-Repo, U.E. |
| Pihlajaniemi, T(aina) |
| Pirttiniemi, P(ertti) |
| Puistola, U(lla) |
| Rajaniemi, H.J. |
| Räsänen, P. |
| Raustia, A. |
| Remes, A(nne) |
| Risteli, J. |
| Ristiniemi, J. |
| Ruddock, L.W. |
| Ruokonen, A. |
| Ryynänen, M. |
| Saarakkala, S. |
| Saari, A. |
| Salo, T(uula) |
| Sándor, G(eorge) K. |
| Savolainen, E-R. |
| Savolainen, M.J. |
| Savolainen, O. |
| Sillanpää, M(ikko). |
| Soininen, R. |
| Sorri, M. |
| Taanila, A. |
| Tapiainen, T(erhi) |
| Tervonen, O(smo) |
| Timonen, M(arkku) |
| Turpeenniemi-Hujanen, T. |
| Tuukkanen, J(uha) |
| Tuulonen, A. |
| Uhari, M. |
| Ukkola, O(lavi) |
| Uusimaa, J. |
| Vainio, O. |
| Vainio, S. |
| Väyrynen, J(uha) P. |
| Veijola, J(uha) |
| Veijola, R(iitta) |
| Virokannas, H. |
| Voipio, H(anna)-M(arja) |
| Vuolteenaho, O. |
| Weckström, M. |
| Wei, GH. |
| Wierenga, R.K. |
| Winqvist, R(obert) |
| Ylänne, J. |
| Ylitalo, K(ari) |
Scholar Chart >>
|
»My Articles
»Latest Feeds
»Popular Feeds |
| | Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma. | Turpeenniemi-Hujanen, T. | 363 days | save |  |  |  | |
| Prognostic significance of Twist, ZEB1 and Slug in peripheral T-cell lymphomas. | Turpeenniemi-Hujanen, T. | 365 days | save | | | | |
| Thioredoxin-1 as a biological predictive marker for selecting diffuse large B-cell lymphoma patients for etoposide-containing treatment. | Turpeenniemi-Hujanen, T. | 444 days | save | | | | |
| Significance of bulky mass and residual tumor-Treated with or without consolidative radiotherapy-To the risk of relapse in DLBCL patients. | Turpeenniemi-Hujanen, T. | 518 days | save | | | | |
| Twist and Zeb1 expression identify Mycosis fungoides patients with low risk of disease progression. | Turpeenniemi-Hujanen, T. | 622 days | save | | | | |
| Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects. | Turpeenniemi-Hujanen, T. | 630 days | save | | | | |
| Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma. | Turpeenniemi-Hujanen, T. | 648 days | save | | | | |
| Incidence of solid cancer in patients with follicular lymphoma. | Turpeenniemi-Hujanen, T. | 692 days | save | | | | |
| Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era. | Turpeenniemi-Hujanen, T. | 721 days | save | | | | |
| Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP. | Turpeenniemi-Hujanen, T. | 861 days | save | | | | |
| Treatment of Diffuse Large B-cell Lymphoma in Elderly Patients; Replacing Doxorubicin with either Epirubicin or Etoposide (VP-16). | Turpeenniemi-Hujanen, T. | 908 days | save | | | | |
| Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP. | Turpeenniemi-Hujanen, T. | 991 days | save | | | | |
| Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial. | Turpeenniemi-Hujanen, T. | 1118 days | save | | | | |
| Case Report: Chemotherapy in Conjunction With Blood-Brain Barrier Disruption for a Patient With Germ Cell Tumor With Multiple Brain Metastases. | Turpeenniemi-Hujanen, T. | 1120 days | save | | | | |
| R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma. | Turpeenniemi-Hujanen, T. | 1190 days | save | | | | |
| Strong Prolyl Hydroxylase Domain 1 Expression Predicts Poor Outcome in Radiotherapy-treated Patients with Classical Hodgkin's Lymphoma. | Turpeenniemi-Hujanen, T. | 1274 days | save | | | | |
| Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma. | Turpeenniemi-Hujanen, T. | 1384 days | save | | | | |
| Low Rap1-interacting factor 1 and sirtuin 6 expression predict poor outcome in radiotherapy-treated Hodgkin lymphoma patients. | Turpeenniemi-Hujanen, T. | 1414 days | save | | | | |
| Real-time monitoring of human blood-brain barrier disruption. | Turpeenniemi-Hujanen, T. | 1556 days | save | | | | |
| Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL). | Turpeenniemi-Hujanen, T. | 1708 days | save | | | | |
| Strong KDM4B and KDM4D Expression Associates with Radioresistance and Aggressive Phenotype in Classical Hodgkin Lymphoma. | Turpeenniemi-Hujanen, T. | 1741 days | save | | | | |
| Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry. | Turpeenniemi-Hujanen, T. | 1849 days | save | | | | |
| Total peroxiredoxin expression is associated with survival in patients with follicular lymphoma. | Turpeenniemi-Hujanen, T. | 1924 days | save | | | | |
| Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study. | Turpeenniemi-Hujanen, T. | 2174 days | save | | | | |
| High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of International Prognostic Index. | Turpeenniemi-Hujanen, T. | 2241 days | save | | | | |
| Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study. | Turpeenniemi-Hujanen, T. | 2295 days | save | | | | |
| Antithrombin III is probably not a suitable biomarker for diagnosis of primary central nervous system lymphoma. | Turpeenniemi-Hujanen, T. | 2312 days | save | | | | |
| Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas. | Turpeenniemi-Hujanen, T. | 2637 days | save | | | | |
| Combination of strong MMP-2 and weak TIMP-2 immunostainings is a significant prognostic factor in endometrial carcinoma. | Turpeenniemi-Hujanen, T. | 2744 days | save | | | | |
| [Chemotherapy in conjunction with blood brain barrier disruption in the treatment of primary central nervous system lymphoma]. | Turpeenniemi-Hujanen, T. | 2794 days | save | | | | |
| Increased expression of CIP2A in aggressive subtypes of B-cell lymphoma. | Turpeenniemi-Hujanen, T. | 2918 days | save | | | | |
| Cell cycle regulation score predicts relapse-free survival in non-germinal center diffuse large B-cell lymphoma patients treated by means of immunochemotherapy. | Turpeenniemi-Hujanen, T. | 2998 days | save | | | | |
| Circulating matrix metalloproteinases MMP-9 and MMP-2/TIMP-2 complex are associated with spontaneous early pregnancy failure. | Turpeenniemi-Hujanen, T. | 3080 days | save | | | | |
| 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. | Turpeenniemi-Hujanen, T. | 3088 days | save | | | | |
| Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma. | Turpeenniemi-Hujanen, T. | 3122 days | save | | | | |
| Biological roles and prognostic values of the epithelial-mesenchymal transition-mediating transcription factors Twist, ZEB1 and Slug in diffuse large B-cell lymphoma. | Turpeenniemi-Hujanen, T. | 3128 days | save | | | | |
| Snail promotes an invasive phenotype in lung carcinoma. | Turpeenniemi-Hujanen, T. | 3138 days | save | | | | |
| Tumor tissue inhibitor of metalloproteinases-1 (TIMP-1) in hormone-independent breast cancer might originate in stromal cells, and improves stratification of prognosis together with nodal status. | Turpeenniemi-Hujanen, T. | 3369 days | save | | | | |
| Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma. | Turpeenniemi-Hujanen, T. | 3437 days | save | | | | |
| Long-term prognosis of breast cancer detected by mammography screening or other methods. | Turpeenniemi-Hujanen, T. | 3464 days | save | | | | |
| Expression and Prognostic Evaluation of Oxidative Stress Markers in an Immunohistochemical Study of B-cell Derived Lymphomas. | Turpeenniemi-Hujanen, T. | 3563 days | save | | | | |
| Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. | Turpeenniemi-Hujanen, T. | 3570 days | save | | | | |
| Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma : a retrospective archival study. | Turpeenniemi-Hujanen, T. | 3710 days | save | | | | |
| 8-hydroxydeguanosine and nitrotyrosine are prognostic factors in urinary bladder carcinoma. | Turpeenniemi-Hujanen, T. | 3724 days | save | | | | |
| A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53. | Turpeenniemi-Hujanen, T. | 3775 days | save | | | | |
| Very high quantitative tumor HER2 content and outcome in early breast cancer. | Turpeenniemi-Hujanen, T. | 3794 days | save | | | | |
| Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. | Turpeenniemi-Hujanen, T. | 3802 days | save | | | | |
| p53 in head and neck cancer: Functional consequences and environmental implications of TP53 mutations. | Turpeenniemi-Hujanen, T. | 3842 days | save | | | | |
| Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial. | Turpeenniemi-Hujanen, T. | 4087 days | save | | | | |
| Increased matrix metalloproteinases 2 and 9 and tissue inhibitor of matrix metalloproteinase 2 expression is associated with progression from vulvar intraepithelial neoplasia to invasive carcinoma. | Turpeenniemi-Hujanen, T. | 4163 days | save | | | | |
| | 
report | next » | | |
|
